ストックスクリーナーアプリを入手
37.90
0.69%
0.285
前日終値:
$37.62
開ける：
$37.7
24時間の取引高:
57,750
Relative Volume:
0.02
時価総額：
$4.48B
収益：
$1.29B
当期純損益:
$251.00M
株価収益率:
19.20
EPS:
1.9744
ネットキャッシュフロー:
$-193.86M
1週間 パフォーマンス:
+8.58%
1か月 パフォーマンス:
-4.12%
6か月 パフォーマンス:
+3.48%
1年 パフォーマンス:
+169.18%
1日の値動き範囲:
$37.65
$38.25
1週間の範囲:
$32.41
$38.52
52週間の値動き範囲:
$13.42
$41.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
37.94 | 4.45B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
15.78 | 49.29B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.55 | 39.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.975 | 40.34B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.00 | 33.30B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.42 | 23.34B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
Indivior Pharmaceuticals, Inc. Statistics – LSX:A42086 - TradingView
Operating expenses (excl. COGS) of Indivior Pharmaceuticals, Inc. – XETR:E7P - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
INDV Technical Analysis | Trend, Signals & Chart Patterns | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Indivior Pharmaceuticals Inc (INDV) Stock Up 5.1% but GF Value S - GuruFocus
Net margin % of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Quick ratio of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted net income available to common stockholders of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
After tax other income/expense of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Non-controlling/minority interest of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Book value per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Operating income of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted earnings per share (diluted EPS) of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Indivior Pharmaceuticals, Inc. Income Statement – LSX:A42086 - TradingView
Cash per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
ETFs Investing in Indivior Pharmaceuticals, Inc. Stocks - TradingView
EBITDA margin % of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Net income of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Zacks.com featured highlights include Indivior, ReNew Energy, Lifetime, NetScout and TEEKAY - The Globe and Mail
Indivior Pharmaceuticals Drops 6.3% Amid Sector-Wide Selling - AlphaStreet
Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096 - GlobeNewswire Inc.
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - TradingView
INDV Stock Chart | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
What to Know About This Fund's $74.8 Million Indivior Sale - The Globe and Mail
Madison Avenue Partners Buys Large Stake in Indivior - HarianBasis.co
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200% - The Globe and Mail
Indivior Pharmaceuticals, Inc. Balance Sheet – DUS:E7P - TradingView
Indivior Pharmaceuticals, Inc. Revenue Breakdown – DUS:E7P - TradingView
Indivior Pharmaceuticals Inc. (INDV) upgraded to strong buy: Here's what you should know - MSN
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After A Strong Multi‑Month Share Price Run - Sahm
Bears are losing control over Indivior Pharmaceuticals Inc. (INDV), here's why it's a 'buy' now - MSN
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Free cash flow of Indivior Pharmaceuticals, Inc. – GETTEX:E7P - TradingView
Equity in earnings of Indivior Pharmaceuticals, Inc. – GETTEX:E7P - TradingView
Indivior Pharmaceuticals, Inc. Revenue Breakdown – GETTEX:E7P - TradingView
Does Indivior Pharmaceuticals Inc. (INDV) have the potential to rally 32.48% as Wall Street analysts expect? - MSN
Does Indivior Pharmaceuticals Inc. (INDV) Have the Potential to Rally 32.48% as Wall Street Analysts Expect? - Yahoo Finance
Indivior launches $175M accelerated share buyback - MSN
Indivior (INDV) Shows Benefits of Sublocade for Opioid Use Disor - GuruFocus
Debt to assets ratio of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Net margin % of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Price to cash flow ratio of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Preferred dividends of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Revenue Breakdown – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Income Statement – MUN:E7P - TradingView
Book value per share of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Earnings and Revenue – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Balance Sheet – MUN:E7P - TradingView
Monthly addiction shot tied to fewer relapses, hospital visits - Stock Titan
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
Indivior Pharmaceuticals Inc (INDV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kingsley Stuart A | Director |
Mar 06 '26 |
Buy |
31.86 |
940 |
29,953 |
5,582 |
| Ryan Barbara | Director |
Mar 09 '26 |
Buy |
32.56 |
31 |
1,009 |
5,716 |
| Ryan Barbara | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
1,963 |
| Humphreys Keith | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
5,802 |
| NINIVAGGI DANIEL A | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,923 |
| Stejbach Mark | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,847 |
| Wheadon David E. | Director |
Jan 05 '26 |
Buy |
35.39 |
1,771 |
62,680 |
14,395 |
2.35%
0.15%
大文字化:
|
ボリューム (24 時間):